Tolcapone is under clinical development by Corino Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Tolcapone’s likelihood of approval (LoA) and phase transition for Amyloidosis took place on 10 Oct 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tolcapone Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Tolcapone (CRX-1008) is under development for the prevention and treatment of familial transthyretin amyloidosis (ATTR), familial amyloid polyneuropathy (FAP/hereditary transthyretin amyloidosis), familial amyloid cardiomyopathy (FAC), senile systemic amyloidosis (SSA) and Leptomeningeal Amyloidosis. The drug candidate is administered orally and is a repurposed drug. The drug candidate targets transthyretin. It is developed based on the in silico ligand-based virtual screening repositioning technology.
Corino Therapeutics overview
Corino Therapeutics ( Corino) is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative products for the treatment of a variety of human diseases, particularly orphan indications. Corino is headquartered in the US.
Quick View Tolcapone LOA Data
|Highest Development Stage|